Drug-induced PML: a global agenda for a global challenge

Author(s): Vinhas de Souza M, Keller-Stanislawski B, Blake K, Hidalgo-Simon A, Arlett P, et al.


The occurrence of severe adverse events such as progressive multifocal leukoencephalopathy (PML) has the potential to limit the benefits of highly efficacious medicines being developed to fulfill unmet clinical needs across therapeutic areas. Following an Expert meeting in London in July 2011 (http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500111562.pdf), a research agenda, highlighting methodological, clinical, and communication elements, to mitigate the risk and improve the management of drug-induced PML has been agreed upon.

Similar Articles

Novel therapeutic options for multiple sclerosis

Author(s): Curtin F, Hartung HP

Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments

Author(s): Achiron A, Barak Y, Gail M, Mandel M, Pee D, et al.

Managing the risks of immunosuppression

Author(s): Riminton DS, Hartung HP, Reddel SW

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Author(s): Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, et al.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

Author(s): Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, et al.

Clinical prognostic factors in multiple sclerosis: a natural history review

Author(s): Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC